news, journals and articles from all over the world.
Since its days as the National Reactor Testing Station, Idaho National Laboratory (INL) has focused on proving that what people think can’t be done is in fact possible. In the past decade, the lab has repeatedly demonstrated to the U.S. Department of Energy (DOE) and the nuclear industry that it can complete large, complicated nuclear projects on time and under budget.
The Endocrine Society is delighted to announce that Lily Ng, PhD, and Douglas Forrest, Ph.D., have won the Society’s 2024 Endocrine Images Art Competition for their image of the astrocyte cell that expresses type 2 deiodinase.
Bacteria are nearly ubiquitous and have tremendous impacts on human and ecological health. And yet, they remain largely mysterious to us. Princeton MOL faculty Zemer Gitai, Britt Adamson and Ned Wingreen launched a joint effort to develop new tools to help us better understand bacteria.
Artificial intelligence’s impact goes beyond clinical medicine. It is reshaping science in more profound ways.
Chula opens a state-of-the-art innovation center for veterinary students to practice their clinical skills with a simulated and modern lab classroom to hone students’ skills and develop their expertise and a space for international training to promote veterinary and medical education.
With the recent announcement of the RegeneratOR Test Bed to support regenerative medicine start up companies, the Wake Forest Institute for Regenerative Medicine (WFIRM) and the RegenMed Development Organization (RemDO) are embarking on the next step – to help create the future workforce.
The College of American Pathologists (CAP) earned reapproval from the Centers for Medicare & Medicaid Services (CMS) as an accreditation organization for clinical laboratories.
The IFCC announces the IFCC Global Conference on COVID-19 that will take place virtually on February 15-17, 2021. The theme of this conference will be the “Critical Role of Clinical Laboratories in the COVID-19 Pandemic”.
New glucose reference correlation analyzer replaces “gold standard” YSI 2300
Altitude Lab announced its first resident companies and opened applications for its breakthrough collaborative facility and program. It’s the first of its kind—a blended incubator/accelerator program focused on developing diverse and inclusive early-stage life science and health care companies in Utah.
Rutgers’ RUCDR Infinite Biologics received an amended emergency use authorization from the FDA late Thursday for the first SARS-CoV-2 coronavirus test that will allow people to collect their own saliva at home and send to a lab for results. The decision follows the FDA’s recent emergency approval to RUCDR Infinite Biologics for the first saliva-based test, which involves health care workers collecting saliva from individuals at testing sites.
Rutgers’ RUCDR Infinite Biologics has launched a test for the SARS-CoV-2 coronavirus and is using its automation experience and infrastructure to test as many as tens of thousands of samples daily. RUCDR has also submitted an emergency use authorization request for a saliva collection method that will allow for broader population screening.
As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there’s reassuring evidence that children have fewer symptoms and less severe disease. That’s among the insights provided by an expert review in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
As outbreaks of COVID-19 disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue worldwide, there’s reassuring evidence that children have fewer symptoms and less severe disease. That’s among the insights provided by an expert review in The Pediatric Infectious Disease Journal, the official journal of The European Society for Paediatric Infectious Diseases. The journal is published in the Lippincott portfolio by Wolters Kluwer.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu